Arrowhead's plozasiran cuts acute pancreatitis event rates 78% versus placebo in pooled trials
Bitget2026/11/07 21:15- Arrowhead Pharmaceuticals presented plozasiran and ARO-DIMER-PA clinical results at the American Heart Association Scientific Sessions 2026.
- Pooled SHASTA-3/4 results showed plozasiran reduced acute pancreatitis rates versus placebo in severe hypertriglyceridemia, particularly among patients with recent pancreatitis.
- The PALISADE extension showed sustained triglyceride reductions through three years in familial chylomicronemia syndrome; findings lacked a concurrent placebo control.
- Early-stage ARO-DIMER-PA results showed simultaneous LDL cholesterol and triglyceride reductions following single doses; reported changes were not placebo-adjusted.
- Injection-site redness was common with ARO-DIMER-PA; no serious adverse events occurred, though longer-term safety and potential cardiovascular benefits require further study.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
